Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: There are limited data on the use of advanced therapies to treat psoriatic arthritis (PsA) in Russia. Guselkumab, an interleukin (IL)-23p19-subunit inhibitor, demonstrated efficacy in patients with PsA in the phase 3 DISCOVER-1 and -2, and COSMOS trials. This analysis evaluated the efficacy and safety of guselkumab in patients with PsA in Russia.
Methods: This post hoc analysis of DISCOVER-1 and -2 included 1002 biologic-naïve patients with active PsA from Russia (n = 317) and the rest of the world (RoW; n = 685). Patients received guselkumab 100 mg every 4 weeks (Q4W), or at week 0 and 4 then Q8W, or placebo then guselkumab Q4W at week 24 (Russian: n = 119, 88, and 110, respectively; RoW: n = 216, 246, and 223, respectively). Outcomes through week 52 were pooled (DISCOVER-1 and -2); outcomes from week 52 to 100 represent DISCOVER-2 only.
Results: In patients from Russia, ≥ 20% improvement in the American College of Rheumatology (ACR20) criteria response rates were higher with guselkumab vs. placebo at week 24, increased through week 52, and were consistent across all guselkumab-treated groups at week 100. Similar trends were generally observed for ACR50, ≥ 90% improvement in Psoriasis Area and Severity Index (PASI90), achievement of Disease Activity in Psoriatic Arthritis (DAPSA) low disease activity/remission and minimal disease activity, enthesitis and dactylitis resolution, ≥ 0.35 improvement in Health Assessment Questionnaire-Disability Index (HAQ-DI) score, improvement in patient-reported pain, and measures in patients with axial PsA (including Bath Ankylosing Spondylitis Disease Activity Index [BASDAI], Ankylosing Spondylitis Disease Activity Score [ASDAS], and patient-reported spinal pain). Efficacy responses were similar between patients from Russia and the RoW across all endpoints and timepoints. The safety profile of guselkumab in patients from Russia was consistent with previous findings.
Conclusion: This analysis demonstrated that the safety and efficacy profiles of guselkumab across all PsA domains and patient-reported outcomes in patients from Russia were similar to those in patients from the RoW.
Trial Registration Numbers: NCT03162796 and NCT03158285.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11557812 | PMC |
| http://dx.doi.org/10.1007/s40744-024-00713-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of the work of the inpatient military hospital during the Russian-Ukrainian war.
Pol Merkur Lekarski
September 2025
POLTAVA STATE MEDICAL UNIVERSITY, POLTAVA, UKRAINE.
Objective: Aim: The aim of this work is to analyze the provision of medical care to military personnel on the example of the activities of the Poltava Military Hospital (Poltava, Ukraine) for the period 2021-2023.
Patients And Methods: Materials and Methods: The design of our study was descriptive. During the research, the reporting and accounting documentation of the Poltava Military Hospital for the relevant years was used.
One- versus two-stent stenting strategies in coronary bifurcation lesions.
J Invasive Cardiol
September 2025
Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota. Email:
Objectives: Additional studies are needed on the follow-up outcomes of 1- vs 2-stent techniques in bifurcation percutaneous coronary interventions (PCI).
Methods: The authors examined the angiographic and procedural characteristics, and outcomes of 1306 bifurcation PCIs (1139 patients) performed at 6 centers between 2014 and 2024 from the PROGRESS-BIFURCATION registry.
Results: Upfront 1-stent PCI (96.
Genetic variants in HSP40 co-chaperones modulate ischemic heart disease risk.
Mol Biol Rep
September 2025
Laboratory of Genomic Research, Research Institute for Genetic and Molecular Epidemiology, Kursk State Medical University, Kursk, 305041, Russia.
Background: The chaperoning system, which is responsible for protein homeostasis, plays a significant role in cardiovascular diseases. Among molecular chaperones or heat shock proteins (HSPs), the HSP40 family, the main co-chaperone of HSP70, remains largely underexplored, especially in ischemic heart disease (IHD) risk.
Materials And Results: We genotyped 834 IHD patients and 1,328 healthy controls for three SNPs (rs2034598 and rs7189628 DNAJA2 and rs4926222 DNAJB1) using probe-based real-time PCR.
Antifungal Prescribing in European Pediatric Intensive Care Units: Results of a multinational 3-month weekly point-prevalence survey.
J Pediatric Infect Dis Soc
September 2025
Infectious Diseases Unit, 3rd Department of Pediatrics, Aristotle University School of Medicine, Hippokration Hospital, Thessaloniki, Greece.
Background: Critically ill pediatric patients admitted to the PICU are highly vulnerable to infections, including invasive fungal diseases and antifungal agents are frequently prescribed. Little is known about antifungal usage in PICUs across Europe.
Methods: A multinational 3-month weekly point-prevalence study for measuring antifungal drug use was organized.
Vulvar and vaginal cancer during pregnancy: A pooled analysis of 15 cases from the International Network on Cancer, Infertility and Pregnancy and review of the literature.
Acta Obstet Gynecol Scand
September 2025
Unit of Gynecological Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.
Introduction: Vulvovaginal cancer in pregnancy is rare. Limited data complicate decision-making and patient counseling. Our review, coupled with new case data, fills a current gap in the literature and provides practical insights.
View Article and Find Full Text PDF